

# CONTENTS

<b>Mitchell Fuerst and Christine Humphrey</b> <i>Partners, Fuerst Humphrey Ittleman PL</i> <i>ASSISTING AND DEFENDING CLIENTS</i> <i>IN OVERCOMING VIOLATIONS AND</i> <i>RESOLVING COMPLIANCE SITUATIONS</i>	7
<b>Christopher L. Hagenbush</b> <i>Partner, Patton Boggs LLP</i> <i>COMPLIANCE ISSUES AND CHALLENGES</i> <i>FOR FOOD AND DRUG INDUSTRY CLIENTS</i>	31
<b>Mark C. Levy</b> <i>Partner, Saul Ewing LLP</i> <i>DEFENDING A PHARMACEUTICAL, MEDICAL</i> <i>DEVICE, OR BIOTECHNOLOGY CLIENT</i> <i>IN A GOVERNMENT INVESTIGATION:</i> <i>KEY ISSUES FOR CLIENTS AND ATTORNEYS</i>	47
<b>Heather E.A. Watts</b> <i>Partner, Deeth Williams Wall LLP</i> <i>CANADIAN FOOD AND DRUG LAW</i> <i>ENFORCEMENT TRENDS AND ISSUES</i>	65
<b>Claudia Lewis-Eng</b> <i>Partner, Venable LLP</i> <i>WORKING AMICABLY WITH THE FDA</i>	79
<b>Appendices</b>	91

# Appendices

<b>Appendix A: Summary of Laws Enforced by the FDA</b>	<b>92</b>
<b>Appendix B: FDA Guide to Self-Inspection</b>	<b>97</b>
<b>Appendix C: FDA Compliance Program Guidance Manual Information</b>	<b>114</b>
<b>Appendix D: FDA Issues “Good Reprint Practices Guidance”</b>	<b>120</b>